IL2, interleukin 2, 3558

N. diseases: 950; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE After interleukin-2 expansion of TIL from renal and lung carcinoma and melanoma biopsy tissues, rearrangements of TCR beta-chain genes were analyzed by Southern blotting. 1314129 1992
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Three out of 14 PDS revealed high levels of CD8-positive tumor-infiltrating T-lymphocytes (TILs), also showing elevated levels of immune-related cytokines such as IL1A, IL2, as well as markers that were very recently linked to enhanced response of immunotherapy in malignant melanoma, including CD27, and CD40L. 30963193 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In a phase I trial designed to study a vaccine composed of autologous tumor cells and interleukin-2 gene transfected fibroblasts we analyzed lymphocytes infiltrating the vaccination site (VIL) in two melanoma patients. 9151215 1997
CUI: C0025202
Disease: melanoma
melanoma
0.400 Therapeutic disease CTD_human Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma. 16260693 2005
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Although IL-2 as a single agent has numerous side effects, it remains the important cytokine for PBL activation in melanoma immunotherapy. 28282548 2017
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE A similar association is here proposed to exist between RAS oncogene activation (mutation) in human melanoma and susceptibility of these tumours to the lytic action of activated lymphocytes (both lymphokine-activated killers and cytotoxic T cells) which have been used, along with IL-2, in the adoptive immunotherapy of advanced melanomas. 1643431 1992
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. 10757353 2000
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma. 30303516 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In this study, we demonstrate in the aggressive B16F10 mouse melanoma model that concomitant application of the anti-TRP1 Ab (clone TA99) with TLR3-7/8 or -9 ligands, and IL-2 strongly enhanced tumor control in a therapeutic setting. 30397036 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE In addition, fibroblasts genetically engineered to express (antibody-defined) melanoma-associated antigens and to secrete IL-2 (RLBA-IL-2) were injected either intracerebrally or subcutaneously into mice bearing IC melanoma. 9316052 1997
CUI: C0025202
Disease: melanoma
melanoma
0.400 Therapeutic disease CTD_human Combined chemoimmunotherapy of metastatic melanoma: a single institution experience. 15917704 2005
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Recombinant IL-10 and melanoma supernatants were found to inhibit production of TNF-alpha, IFN-gamma, IL-2 and mixed lymphocyte reactions but reversal of these effects of melanoma supernatants by MAbs against IL-10 was only seen in the case of TNF-alpha production. 8314354 1994
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Peripheral blood lymphocytes of a melanoma patient (AV) were activated in an autologous-mixed-lymphocyte tumor culture (AMLTC) and responding cells were cloned using irradiated autologous melanoma cells (AV-Mel) as antigen source, EBV-transformed B-lymphoblasts as feeder cells and recombinant Interleukin 2. 2159436 1990
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE These results indicated that vaccination with a truncated survivin vaccine using DNA prime-rAd boost combined with IL-2 adjuvant and carboplatin represents an attractive strategy to overcoming immune tolerance to tumors and has potential therapeutic benefits in melanoma cancer. 22706381 2012
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE We hypothesize that a recombinant NDV expressing IL-2 would be an effective agent for therapy of malignant melanoma. 19242529 2009
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE High-dose IL2, first approved in 1992, has been used in the treatment of advanced renal cell carcinoma and melanoma. 30318089 2018
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease LHGDN To attempt to sustain their survival after IL-2 withdrawal, melanoma-reactive human T lymphocytes were retrovirally transduced with an exogenous human IL-2 gene. 11714800 2001
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE These results suggested that tumor-specific CD8+ T cells in melanoma tumor digests are largely PD-1, and this population can recover function after culturing in interleukin-2. 20948441 2011
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE We further show that defective IL-2 secretion in response to melanoma antigens was not due to a T cell clone refractoriness induced by the culture, since one of these clones could be induced to secrete IL-2 by an antigen-expressing melanoma line, upon increased lymphocyte function associated antigen-3 expression induced by gene transfection. 8562498 1995
CUI: C0025202
Disease: melanoma
melanoma
0.400 Therapeutic disease CTD_human Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma. 15577323 2004
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma. 9742914 1998
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. 16224276 2006
CUI: C0025202
Disease: melanoma
melanoma
0.400 Therapeutic disease CTD_human Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma. 18176117 2008
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE Potentially, IL-2/IFN might represent a treatment option in patients with active melanoma after established initial treatment with checkpoint inhibitors and BRAF/MEK-targeted therapies. 31108244 2019
CUI: C0025202
Disease: melanoma
melanoma
0.400 Biomarker disease BEFREE We identified 229 patients with melanoma treated with immune therapies [IL2, ipilimumab, or anti-programmed cell death-1/ligand-1 (PD-1/PD-L1)] at three centers and compared clinical outcomes following immune therapy for patients with or without NRAS mutations. 25736262 2015